Erythromycin ototoxicity: A call to heighten recognition

Cynthia Whitener, J. E. Parker, N. L. Lapp

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Bilateral sensorineural hearing loss developed in a 64-year-old woman treated with intravenous erythromycin lactobionate for bacteremic pneumococcal pneumonia. Discontinuance of the antibiotic led to prompt correction of the hearing deficit. Reversible hearing loss is an infrequently described adverse effect attributed to high-dose erythromycin therapy. Possible risk factors, including age, gender, and hepatic and renal function, may contribute to the development of erythromycin ototoxicity.

Original languageEnglish (US)
Pages (from-to)1214-1216
Number of pages3
JournalSouthern Medical Journal
Issue number10
StatePublished - Dec 3 1991

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Erythromycin ototoxicity: A call to heighten recognition'. Together they form a unique fingerprint.

Cite this